Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.

about

Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.

Item

http://www.wikidata.org/entity/Q42925679

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@en

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@nl

type

Item

label

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@en

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@nl

prefLabel

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@en

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@nl

P1476

Antitumor Vaccines Based on De ...... mor Models to Clinical Trials.

@en

P2093

M A Zenkova

http://www.w3.org/2001/XMLSchema#string

N L Mironova

http://www.w3.org/2001/XMLSchema#string

O V Markov

http://www.w3.org/2001/XMLSchema#string

V V Vlassov

http://www.w3.org/2001/XMLSchema#string

P2860

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

CTLA-4 can function as a negative regulator of T cell activation

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule.

Dendritic cells crosspresent antigens from live B16 cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model.

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.

Nivolumab in NSCLC: latest evidence and clinical potential

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

P304

27-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29104773

http://www.w3.org/2001/XMLSchema#string

P932

5662271

http://www.w3.org/2001/XMLSchema#string